Drug intelligence / Profile preview

BWA-02

Development stage: Preclinical
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BWA-02 is a preclinical-stage small interfering RNA (siRNA) therapeutic developed by Argo Biopharma (Chengdu Xinzhenghe Pharmaceutical Technology) for the treatment of obesity. Utilizing the company's proprietary RNA interference (RNAi) platform, BWA-02 is designed to specifically target and silence the expression of the **Inhibin subunit beta E (INHBE)** gene in the liver. INHBE is a hepatokine that has been identified through human genetics as a regulator of energy homeostasis and fat distribution; its knockdown is associated with reduced abdominal adiposity and improved metabolic profiles. In early 2024, GSK entered into a strategic collaboration and license agreement with Argo Biopharma, which included an option for GSK to license the BWA-02 program following the completion of certain preclinical milestones.

Other names: Argo Biopharma INHBE siRNA

Targets

ASGPR (Asialoglycoprotein Receptor 1)INHBE (Inhibin beta E chain)

Beyond the preview

Go deeper on BWA-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWA-02.

Explore the full profile